Fundraising Fox
Delve Bio
Founded 2022 · 43 employees on LinkedIn · 3 known investors
Find your way into Delve Bio
Sign up to see every warm intro you have to Delve Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Delve Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Delve develops molecular next-generation sequencing (mNGS) tests that diagnose infections in cerebrospinal fluid and other clinical samples, enabling rapid pathogen identification for patients with difficult-to-diagnose infections.
Founders & leadership
Delve Bio was founded in 2022 by Dr. Joseph DeRisi.
Investors · 3
How we know: GV (Google Ventures)'s portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AJun 2023Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Delve Bio do?
- Delve develops molecular next-generation sequencing (mNGS) tests that diagnose infections in cerebrospinal fluid and other clinical samples, enabling rapid pathogen identification for patients with difficult-to-diagnose infections.
- Who founded Delve Bio?
- Delve Bio was founded by Dr. Joseph DeRisi in 2022.
- Who are Delve Bio's investors?
- Delve Bio's investors include GV (Google Ventures), Perceptive Xontogeny Venture, Section 32.